McDermott Wendy 4

What Happened

Wendy McDermott, Senior Vice President of Human Resources at Lexicon Pharmaceuticals (LXRX), received two awards of restricted stock units (RSUs) on February 12, 2026: 250,200 RSUs and 375,300 RSUs, for a total of 625,500 RSUs. The grants were issued at $0.00 (derivative awards), meaning no cash was paid at grant—these are compensation awards that convert to shares if and when they vest.

Key Details

• Transaction type: Award/Grant (Code A) on 2026-02-12. Report filed 2026-02-17 (timely).
• Shares granted: 250,200 RSUs + 375,300 RSUs = 625,500 RSUs; acquisition price reported $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Relevant footnotes:
  • F1: Each restricted stock unit represents a contingent right to receive one share of common stock upon settlement.
  • F2: Vesting: 1/3 of the RSUs vest on February 28 of each of the three years following the year of grant (first vesting likely Feb 28, 2027).
  • F3 appears in the filing but describes an option vesting schedule (25% first anniversary, then monthly) and does not apply to these RSUs.
• No sale or purchase of shares occurred; this is a compensation award.

Context

RSUs are derivative compensation: they do not deliver stock immediately but convert to shares according to the vesting schedule. Such grants are common for employee compensation and do not by themselves indicate buying or selling sentiment. The filing appears timely under Form 4 reporting rules.